Whitehawk Therapeutics to Participate in Upcoming Investor Conferences
Whitehawk Therapeutics (Nasdaq: WHWK), an oncology therapeutics company focused on ADC cancer treatments, has announced its upcoming participation in two major investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Whitehawk Therapeutics (Nasdaq: WHWK), an oncology therapeutics company focused on ADC cancer treatments, has announced its upcoming participation in two major investor conferences. CEO Dave Lennon will engage in fireside chats at the Morgan Stanley Global Healthcare Conference on September 8, 2025 at 4:50 PM ET and the H.C. Wainwright Global Investment Conference on September 9, 2025 at 3:30 PM ET.
Both events will be held in New York City and will feature live webcasts accessible through Whitehawk's IR website, with replays available for approximately 30 days after the events.
Details
News Market Reaction – WHWK
On Sep 2, the day this news came out, WHWK closed 0.83% above the previous close.
Data tracked by StockTitan Argus for the Sep 2 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September 8, 2025. Fireside chat at 4:50 PM ET.
- H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 9, 2025. Fireside chat at 3:30 PM ET.
A live webcast of the fireside chat events can be accessed by visiting the Whitehawk Therapeutics IR website. These will be available for replay for approximately 30 days following the event.
About Whitehawk Therapeutics
Whitehawk Therapeutics is an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement. More information on the Company is available at www.whitehawktx.com and connect with us on LinkedIn.
Contact
IR@whitehawktx.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/whitehawk-therapeutics-to-participate-in-upcoming-investor-conferences-302543271.html
SOURCE Whitehawk Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.